Cargando…
siRNA Targeting and Treatment of Gastrointestinal Diseases
RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environmen...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853152/ https://www.ncbi.nlm.nih.gov/pubmed/31309709 http://dx.doi.org/10.1111/cts.12668 |
_version_ | 1783469988775985152 |
---|---|
author | Chevalier, Rachel |
author_facet | Chevalier, Rachel |
author_sort | Chevalier, Rachel |
collection | PubMed |
description | RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a specific site. This review discusses polymer and lipid‐based delivery systems for protection and targeting of siRNA therapies to the GI tract to treat local disease. |
format | Online Article Text |
id | pubmed-6853152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68531522019-12-16 siRNA Targeting and Treatment of Gastrointestinal Diseases Chevalier, Rachel Clin Transl Sci Reviews RNA interference via small interfering RNA (siRNA) offers opportunities to precisely target genes that contribute to gastrointestinal (GI) pathologies, such as inflammatory bowel disease, celiac, and esophageal scarring. Delivering the siRNA to the GI tract proves challenging as the harsh environment of the intestines degrades the siRNA before it can reach its target or blocks its entry into its site of action in the cytoplasm. Additionally, the GI tract is large and disease is often localized to a specific site. This review discusses polymer and lipid‐based delivery systems for protection and targeting of siRNA therapies to the GI tract to treat local disease. John Wiley and Sons Inc. 2019-08-05 2019-11 /pmc/articles/PMC6853152/ /pubmed/31309709 http://dx.doi.org/10.1111/cts.12668 Text en © 2019 The Author. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Reviews Chevalier, Rachel siRNA Targeting and Treatment of Gastrointestinal Diseases |
title | siRNA Targeting and Treatment of Gastrointestinal Diseases |
title_full | siRNA Targeting and Treatment of Gastrointestinal Diseases |
title_fullStr | siRNA Targeting and Treatment of Gastrointestinal Diseases |
title_full_unstemmed | siRNA Targeting and Treatment of Gastrointestinal Diseases |
title_short | siRNA Targeting and Treatment of Gastrointestinal Diseases |
title_sort | sirna targeting and treatment of gastrointestinal diseases |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853152/ https://www.ncbi.nlm.nih.gov/pubmed/31309709 http://dx.doi.org/10.1111/cts.12668 |
work_keys_str_mv | AT chevalierrachel sirnatargetingandtreatmentofgastrointestinaldiseases |